Imbruvica (ibrutinib) is a cancer medication that interferes with the growth and spread of cancer cells in the body.
Imbruvica is used to treat certain types of non-Hodgkin lymphoma, including mantle cell lymphoma (MCL), Waldenstrom's macroglobulinemia, and chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) in people with or without 17p deletion.
Imbruvica is sometimes given when other medicines have not been effective.
Imbruvica was approved to treat mantle cell lymphoma by the US Food and Drug Administration (FDA) on an "accelerated" basis. In clinical studies, tumors responded to this medicine. However, it has not been shown that ibrutinib can improve symptoms or lengthen survival time in people with this type of lymphoma.
Follow all directions on your medicine label and package. Tell each of your healthcare providers about all your medical conditions, allergies, and all medicines you use.